We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy.
February 20, 2018 – Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial
January 8, 2018 – Xenon Pharmaceuticals Outlines Key Milestones for 2018
December 4, 2017 – Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting
November 8, 2017 – Xenon Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
November 7, 2017 – Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update